Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6369MR)

This product GTTS-WQ6369MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6369MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9170MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ13747MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ6545MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ6025MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ4554MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ7094MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ740MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ11801MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW